The Serious Risks of Methamphetamine Use
Methamphetamine poses dangers to mental and physical health, impacting cognition and behavior.
― 5 min read
Table of Contents
Methamphetamine (MA) is a powerful drug that people often misuse. It is derived from amphetamine, a substance that can stimulate the brain. MA is the second most commonly abused drug after cannabis. Many people use it to feel more energetic, enjoy social situations, boost their mood, and lose weight. However, MA is very addictive, and its misuse has serious consequences for health worldwide due to its easy availability, low cost, and potential for overdose.
The Dangers of Methamphetamine Use
Using MA poses significant risks. People who use it can experience various Mental Health issues, including anxiety, hallucinations, and confusion. About 40% of MA users may show signs similar to schizophrenia, a severe mental disorder. Studies show that nearly 37% of users will experience Psychotic symptoms at some point in their lives. People who are heavily dependent on MA or use high doses are at a greater risk of developing these psychotic symptoms, which can be temporary but may last longer for some users.
Cognitive Impairments Linked to Methamphetamine
MA use is linked to problems in thinking and mental functions. Many users have difficulty with Memory, attention, and decision-making skills. While some research suggests that using MA might temporarily improve certain types of focus or attention, long-term abuse leads to cognitive decline. Interestingly, studies show that even when cognitive impairments are present, they may still be within the normal range for some individuals.
Neurocognitive Functions Affected by Methamphetamine
People who misuse MA often struggle with various mental tasks. They might find it hard to shift their thinking, remember facts, or control their impulses. While MA may seem to boost attention short-term, chronic use harms overall cognitive performance. Studies have highlighted several cognitive areas where users fall behind, particularly in executive functions, verbal skills, and memory tasks.
Physical Biomarkers and Methamphetamine Use
Recent investigations have identified specific physical markers in the body that relate to MA use. These include indicators of stress on the body, such as advanced glycation end products (AGEs) and changes in antioxidant levels. These factors can connect to how severe a person's drug use is and whether they are experiencing psychosis. Results indicate that these biomarkers can explain a significant portion of the differences seen in cognitive performance among MA users.
Understanding Methamphetamine-Induced Psychosis
When individuals consume MA, they can exhibit symptoms similar to psychosis. This includes delusions (false beliefs) and hallucinations (seeing or hearing things that are not real). Most of the time, these symptoms are temporary, but for a small number of users, they can linger. Researchers have noted that the presence of psychotic symptoms in MA users often correlates with their level of drug dependence and the amount they consume.
Research Methods in Studying Methamphetamine Effects
To study the effects of MA, researchers often carry out clinical assessments on both users and healthy individuals. They collect a variety of data, including demographic details and clinical evaluations. Various tests are used to measure cognitive abilities, and biological samples are taken to analyze the presence of specific biomarkers.
Participants in Methamphetamine Studies
In research studies, participants generally include individuals diagnosed with MA use disorder and healthy controls. The focus is often on adult males due to cultural considerations in certain regions. Participants known to have other significant health issues or those with opioid dependencies are usually excluded from studies to ensure data reliability.
Monitoring Mental Health and Cognitive Function
Researchers use various psychological assessments to measure mental health and cognitive function in participants. These evaluations provide insight into how MA use affects thinking and behavior. Tests can cover a range of abilities, such as memory, attention, and decision-making skills.
The Link Between Physical Health and Cognitive Decline
Studies indicate that physical health factors related to MA use can impact cognitive function. For example, measures of Oxidative Stress and antioxidant levels in the body correspond with cognitive performance. Researchers aim to determine how these physical health indicators might reflect the extent of cognitive decline in MA users.
Findings from Methamphetamine Research
Research has revealed some important connections between MA use, mental health, and cognitive capabilities. Higher levels of oxidative stress in the body appear to correlate with poorer cognitive performance. There is also evidence indicating that as MA use increases, so do the levels of harmful substances in the body that could lead to cognitive issues.
Utilizing Psychological Assessments
Various psychological assessments are used to gauge mental functions, including working memory, verbal skills, and problem-solving abilities. These assessments are crucial for understanding the cognitive challenges faced by MA users. Researchers have found that many people using MA show deficits in these areas, which aligns with their substance use history.
Treating and Managing Methamphetamine Use Disorder
Effective treatments for MA use disorder often include therapy and support programs. Understanding the cognitive and mental health implications of MA use is essential for developing personalized treatment plans. Rehabilitation focuses not only on quitting the drug but also on restoring overall mental function and health.
Conclusion: The Impact of Methamphetamine
The use of methamphetamine represents a serious health concern. It leads to numerous potential adverse effects on both mental and physical health. Understanding these impacts, especially regarding cognitive abilities and mental health symptoms, can help guide prevention and treatment efforts. Ongoing research is essential for uncovering the pathway from MA use to cognitive decline and developing effective interventions.
Title: The general neurocognitive decline in patients with methamphetamine (MA) use and transient MA-induced psychosis is primarily determined by oxidative and AGE-RAGE stress.
Abstract: BackgroundChronic methamphetamine (MA) usage is linked to oxidative stress (OS), AGE-RAGE stress, changes in magnesium, calcium, and copper, increased psychotic symptoms and neurocognitive deficits. Nevertheless, it is still unclear whether the latter impairments are mediated by these biological pathways. AimsThe purpose of this study was to investigate the relationships between neurocognition, the aforementioned biomarkers, and psychotic symptoms. MethodsWe recruited 67 participants, namely 40 patients diagnosed with MA-substance use and 27 healthy controls, and assessed the Brief Assessment of Cognition in Schizophrenia (BACS), symptoms of psychosis, excitation, and formal thought disorders, OS toxicity (computed as the sum of myeloperoxidase (MPO), oxidized high-density lipoprotein (HDL), oxidized low-DL, and malondialdehyde), antioxidant defenses (catalase, glutathione peroxidase, total antioxidant capacity, zinc, and HDL), increased advanced glycation end products (AGEs), and soluble AGE receptors. ResultsWe were able to extract one validated latent vector from the Mini Mental State Examination score and the BACS tests results (including executive functions, verbal fluency, attention), labeled general cognitive decline (G-CoDe). We found that 76.1% of the variance in the G-CoDe was explained by increased OS toxicity, lowered antioxidant defenses, number of psychotic episodes, and MA dose. In patients with MA use, MPO was significantly associated with the G-CoDe. ConclusionsThe use of MA induces mild cognitive impairments through MA-induced activation of detrimental outcome pathways, including oxidative and AGE-RAGE stress, and suppression of protective outcome pathways (antioxidants). Increased OS, MPO, and AGE-RAGE stress are new drug targets to prevent neurocognitive deficits and psychosis due to MA use.
Authors: Michael Maes, M. F. Altufaili, A. F. Alhaideri, S. R. Moustafa, K. Stoyanova, M. Niu, B. Zhou, J. Li, H. K. Al-Hakeim
Last Update: 2024-04-03 00:00:00
Language: English
Source URL: https://www.medrxiv.org/content/10.1101/2024.04.02.24305184
Source PDF: https://www.medrxiv.org/content/10.1101/2024.04.02.24305184.full.pdf
Licence: https://creativecommons.org/licenses/by/4.0/
Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.
Thank you to medrxiv for use of its open access interoperability.